Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gross profit | 14,457 | 6,389 |
| Operating expenses: | ||
| Research and development | 13,017 | 8,302 |
| Selling, general and administrative | 13,787 | 6,640 |
| Total operating expenses | 26,804 | 14,942 |
| Loss from operations | (12,347) | (8,553) |
| Interest income, net | 539 | 786 |
| Interest expense | (223) | (46) |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's SG&A?
- Alamar Biosciences (ALMR) reported SG&A of $13.79M in Q1 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Alamar Biosciences's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude